3D Tumor Models in Oncology Therapeutic Discovery
Oncology is one of the fastest-moving therapeutic areas, which also makes it a highly competitive and complex space. Pharmaceutical companies are facing major challenges during early drug development due to the lack of optimal preclinical models for the evaluation of activity and safety, which leads to unsuccessful clinical trials.
In this webinar, Dr. Laure-Anne Ligeon, Oncology and Immuno-Oncology Team Lead, and Dr. Nils Goedecke, Product Owner Cryo delve into:
- the importance of adopting 3D tumor models that closely mimic the complexity and heterogeneity of the tumor microenvironment
- the biological and economic benefits of maintaining uniform composition and size between spheroids, enabling high scalability, reliability, and reproducibility
Gain valuable insights on how 3D cancer models are used to evaluate the efficacy and the mechanism of action of promising anti-cancer drugs. Our expert speakers demonstrate how InSphero’s 3D InSight™ Oncology platform can help determine the ability of therapeutic candidates to penetrate the tumor, providing reliable and physiologically relevant results for early-stage decisions.
Key learning objectives
- Discover the advantages of 3D human tumor spheroids over traditional 2D and animal testing in early drug development
- Learn how to select the right 3D tumor spheroids for your biological questions
- Gain insight into drug testing and readouts using complex 3D tumor models